Arcadia Biosciences, Inc. (RKDA)
| Market Cap | 2.20M -60.7% |
| Revenue (ttm) | 4.76M -9.5% |
| Net Income | -9.32M |
| EPS | -6.03 |
| Shares Out | 2.06M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 202,603 |
| Open | 1.000 |
| Previous Close | 1.030 |
| Day's Range | 0.940 - 1.080 |
| 52-Week Range | 0.800 - 6.710 |
| Beta | 0.50 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 14, 2026 |
About RKDA
Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.
Financial Performance
In 2025, Arcadia Biosciences's revenue was $4.86 million, a decrease of -3.71% compared to the previous year's $5.05 million. Losses were -$2.34 million, -66.77% less than in 2024.
Financial StatementsNews
Arcadia Biosciences Quarterly report: Q1 2026
Arcadia Biosciences has published its Q1 2026 quarterly earnings report on May 14, 2026.
Arcadia Biosciences Earnings release: Q1 2026
Arcadia Biosciences released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Arcadia Biosciences Annual report: Q4 2025
Arcadia Biosciences has published its Q4 2025 annual report on March 26, 2026.
Arcadia Biosciences Earnings release: Q4 2025
Arcadia Biosciences released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
Arcadia Biosciences Registration statement: Registration Filing
Arcadia Biosciences filed a registration statement on January 28, 2026, providing details about a securities offering with the SEC.
Arcadia Biosciences files to sell 1.67M shares of common stock for holders
06:09 EST Arcadia Biosciences (RKDA) files to sell 1.67M shares of common stock for holders
Arcadia Biosciences Proxy statement: Proxy Filing
Arcadia Biosciences filed a proxy statement on November 19, 2025, providing details for shareholder voting and corporate governance matters.
Arcadia Biosciences Earnings release: Q3 2025
Arcadia Biosciences released its Q3 2025 earnings on November 7, 2025, summarizing the period's financial results.
Arcadia Biosciences Quarterly report: Q3 2025
Arcadia Biosciences has published its Q3 2025 quarterly earnings report on November 7, 2025.
Arcadia Biosciences Quarterly report: Q2 2025
Arcadia Biosciences has published its Q2 2025 quarterly earnings report on August 14, 2025.
Arcadia Biosciences Earnings release: Q2 2025
Arcadia Biosciences released its Q2 2025 earnings on August 14, 2025, summarizing the period's financial results.
Arcadia Biosciences Earnings Call Transcript: Q1 2025
Zola sales surged 90% year-over-year in Q1 2025, outpacing the coconut water category and driving a 22% revenue increase. The company exited its legacy agtech business, monetized IP, and reduced liabilities, while the Roosevelt Resources merger remains on track for completion by August.
Arcadia Biosciences Quarterly report: Q1 2025
Arcadia Biosciences has published its Q1 2025 quarterly earnings report on May 8, 2025.
Arcadia Biosciences Earnings release: Q1 2025
Arcadia Biosciences released its Q1 2025 earnings on May 8, 2025, summarizing the period's financial results.
Arcadia Biosciences reports Q1 revenue $1.2M vs $987k last yea
“The momentum we experienced in the second half of 2024 has continued into 2025, and we are very pleased with our first quarter results,” said T.J. Schaefer, CEO of Arcadia.
Arcadia Biosciences Earnings Call Transcript: Q4 2024
2024 saw a strategic refocus on Zola coconut water, driving 46% sales growth and record distribution gains, while exiting underperforming brands and monetizing legacy assets. Gross margins remained strong, and the Roosevelt Resources transaction is expected to close by Q2 2025.
Arcadia Biosciences Annual report: Q4 2024
Arcadia Biosciences has published its Q4 2024 annual report on March 20, 2025.
Arcadia Biosciences Earnings release: Q4 2024
Arcadia Biosciences released its Q4 2024 earnings on March 20, 2025, summarizing the period's financial results.
Arcadia Biosciences Transcript: M&A Announcement
Arcadia will issue shares to acquire Roosevelt, resulting in Roosevelt owning 90% of the combined entity. The deal enables Roosevelt to advance its large-scale CCUS and EOR project, with the company renamed Roosevelt Resources and led by Roosevelt’s management.
Arcadia Biosciences Press release: M&A Announcement
Arcadia Biosciences issued a press release on December 11, 2024, disclosing material business information to investors.
Arcadia Biosciences Slides: M&A Announcement
Arcadia Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on December 11, 2024.
Arcadia Biosciences to combine with Roosevelt Resources in an all-stock deal
Arcadia Biosciences (RKDA) and Roosevelt Resources announced that they have entered into a definitive securities exchange agreement which, when completed, will combine the two companies in an all-stoc...
Arcadia Biosciences reports Q3 EPS ($1.18), consensus (81c)
Reports Q3 revenue $1.54M, consensus $1.4M.”We are extremely pleased with our third-quarter 2024 results, which represent the progress we have made in transforming Arcadia’s business as well as our ab...
Arcadia Biosciences Earnings Call Transcript: Q3 2024
Q3 2024 saw 18% revenue growth, led by a 55% increase in Zola sales and major distribution gains. Cash burn hit historic lows, and Zola outpaced the coconut water category, with new product launches planned for next year.
Arcadia Biosciences Quarterly report: Q3 2024
Arcadia Biosciences has published its Q3 2024 quarterly earnings report on November 12, 2024.